If you have been reading about albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-02-14. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
在生理层面，GIP 与 GLP-1 均为肠道内分泌细胞分泌的肠促胰素，进食后参与胰岛素分泌调节与胃排空抑制。Tirzepatide 通过同时激活这两条信号通路，使胰岛素分泌的葡萄糖依赖性增强，并延缓冲胃排空、降低食欲信号。与单一 GLP-1 激动相比，双靶点作用在血糖控制和体重变化上的效应幅度更大，但具体贡献比例仍在研究之中。
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
. in a linear manner. Thus, quinoline-based indicators are one-wavelength dyes - the signal results from monitoring the fluorescence at a single wavelength. Ratiometric measurement of halide concentration is not possible with quinolinium dyes. The kinetics of collision quenching are diffusion-limited only, and these indicators provide submillisecond time resolution. Quinolinium-based dyes are insensitive to physiological changes in pH, but they are prone to strong bleaching and demand ultraviolet excitation, which is harmful for living organisms. Because quinolinium is not occurring in the cells naturally, cell loading is necessary. However, quinolinium-based dyes aren't retained perfectly in the cell and can't be targeted easily to subcellular organelles. Also, they cannot be designed specific to a certain type of cell. The most used quinolinium-based Cl− indicators are 6-methoxy-1-(3-sulfonatopropyl) quinolinium (SPQ), 6-methoxy-N-ethylquinolium Cl− (MEQ), and N-(6-methoxyquinolyl)-acetoethyl ester (MQAE).
The adjacent figure shows a typical fission product distribution from the fission of uranium. Note that in the calculations used to make this graph, the activation of fission products was ignored and the fission was assumed to occur in a single moment rather than a length of time. In this bar chart results are shown for different cooling times (time after fission). Because of the stability of nuclei with even numbers of protons and/or neutrons, the curve of yield against element is not a smooth curve but tends to alternate. Note that the curve against mass number is smooth.
=== Viral infection === Many studies have presented evidence for and against association of autism with viral infection after birth. Laboratory rats infected with Borna disease virus show some symptoms similar to those of autism but blood studies of autistic children show no evidence of infection by this virus. Members of the herpes virus family may have a role in autism, but the evidence so far is anecdotal. Viruses have long been suspected as triggers for immune-mediated diseases such as multiple sclerosis but showing a direct role for viral causation is difficult in those diseases, and mechanisms, whereby viral infections could lead to autism, are speculative.
Colombia withdrew from the 1946 South American Championship but won their first international title later that year at the football tournament of the 1946 Central American and Caribbean Games, staged in Barranquilla in December. After Cuba and Mexico withdrew, judging that the strength of the remaining entrants did not justify the cost of sending teams, the competition was played as a single round-robin; Colombia won all six matches, scoring 20 goals and conceding seven, defeating Curaçao, Venezuela, Guatemala, Puerto Rico, Costa Rica and Panama. The team was coached by Peruvian manager José Arana Cruz, one of the first foreign coaches in the Colombia setup, whose tenure coincided with the country's first major international success.
Approximately 24,700,000 tons of ethylbenzene were produced in 1999. Highly instructive but of far less industrial significance is the Friedel-Crafts alkylation of benzene (and many other aromatic rings) using an alkyl halide in the presence of a strong Lewis acid catalyst. Similarly, the Friedel-Crafts acylation is a related example of electrophilic aromatic substitution. The reaction involves the acylation of benzene (or many other aromatic rings) with an acyl chloride using a strong Lewis acid catalyst such as aluminium chloride or Iron(III) chloride.
Sources: en.wikipedia.org
=== Atmosphere of Venus === The Venus Express orbiter collected Venus science data from April 2006 until December 2014. In 2008, Piccioni, et al. reported measurements of night-side airglow emission in the atmosphere of Venus made with the Visible and Infrared Thermal Imaging Spectrometer (VIRTIS) on Venus Express. They attributed emission bands in wavelength ranges of 1.40–1.49 micrometers and 2.6–3.14 micrometers to vibrational transitions of OH. This was the first evidence for OH in the atmosphere of any planet other than Earth.
Most thermal cyclers have heated lids to prevent condensation at the top of the reaction tube. Older thermal cyclers lacking a heated lid require a layer of oil on top of the reaction mixture or a ball of wax inside the tube.
=== Early America === Native Americans had found a way to make ground corn palatable, later called grits (from the Old English word grēot, meaning "gravel"). Hominy was another preparation. While this became a staple in the southern U.S., grits never gained popularity in the northern states. Food reformers in the 19th century called for cutting back on excessive meat consumption at breakfast. They explored numerous vegetarian alternatives. Late in the century, the Seventh-day Adventists based in Michigan made these food reforms part of their religion, and non-meat breakfasts were featured in their sanitariums and led to new breakfast cereals.
=== External electrodes === The advancement of technologies like 3D printing has enabled the creation of electrodes using simple and easily accessible equipment, leading to numerous instances where these electrodes are patterned as standalone units and subsequently integrated with paper-based microfluidic devices. To this end, there have been several examples of a thermoplastic electrode patterning and their use for electrochemical sensing, for example in flow injection analysis.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.